Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Aug 28;11:2085. doi: 10.3389/fmicb.2020.02085

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Gidari, Sabbatini, Schiaroli, Perito, Francisci, Baldelli and Monari.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Percentage of rifampicin-resistant CFU of 48-h-old biofilm of Staphylococcus aureus (A) ATCC 6538 and (B) ATCC 43300 after treatment with different concentrations of antibiotics in combination. Rifampicin-resistant CFU were evaluated by plating biofilm onto TSA plates containing 20 μg/mL rifampicin after 48 h of treatment with the rifampicin-daptomycin and rifampicin-tedizolid combinations. Results from three independent experiments in triplicate are expressed as percentages ± SEM of rifampicin-resistant CFU after treatment. Statistically significant differences were tested with ordinary one-way ANOVA or Kruskal–Wallis test. ^∧p < 0.05 antibiotic combination-treated biofilm rifampicin-resistant CFU vs rifampicin-treated biofilm rifampicin-resistant CFU. Values for all tedizolid + rifampicin combinations are zero, so the bars are not visible in the graph.